INMD

InMode Ltd.

Fundamental data last updated:September 26, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Devices

Exchange

NASDAQ

County of HQ

IL

Next Earnings Date

Pending Announcement

Business Summary

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.

 


VALUATION

P/E

10.22

Market Cap ($M USD)

$890.19M

Forward P/E

9.30

PEG

0.95

PRICE TO SALES

2.38

PRICE TO BOOK

1.35

EV / EBITDA

5.08

5-Year Average P/E

Free Cash Flow Yield

10.18%

DCF Value

$33.43

Graham Number

$17.96

Price to FCF

9.82

EV to FCF

5.52

Earnings Yield

9.79%

FCF Yield

10.18%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$1.38

Next Year EPS Growth Estimate

$1.51

Next Year Revenue Growth Estimate

$389.07M

Return on Equity (ROE)

13.28%

FREE CASH FLOW

Operating Margin

21.31%

Debt-to-Equity

0.02

Piotroski F-Score

7

Altman Z-Score

7.80

Return on Invested Capital (ROIC)

11.85%

Current Ratio

8.80

Quick Ratio

7.88

Net Debt to EBITDA

-3.95

Interest Coverage

0.00

Gross Profit margin

77.84%

FCF PER SHARE

$1.43

REVENUE PER SHARE

$5.91

Gainseekers Quantitative Analysis

Summary

InMode Ltd. appears to be a classic case of market mispricing. With a DCF value significantly higher than recent pricing, the stock seems undervalued. The Forward P/E of 9.58 and an Earnings Yield of 9.85% suggest a compelling valuation, especially when paired with an Altman Z-score of 7.82, indicating robust financial health. This is a company that the market might be overlooking, given its solid fundamentals and growth potential.

AI Exposure / Tech Reliance

Operating in the Medical Devices industry, InMode Ltd. is well-positioned to leverage AI and modern technological advancements. The healthcare sector's increasing reliance on tech-driven solutions provides a fertile ground for innovation. InMode's focus on cutting-edge devices aligns well with these trends, potentially enhancing its competitive edge.

The Bull Case

For the value or GARP investor, InMode Ltd. offers a tantalizing opportunity. With an ROIC of 11.85% and a strong FCF Yield of 10.25%, the company demonstrates impressive capital efficiency and cash generation. A Piotroski F-Score of 7 underscores its solid financial footing, while an operating margin of 21.31% highlights its pricing power. These metrics paint a picture of a company that knows how to convert revenue into profit effectively.

The Bear Case

Despite its strengths, InMode Ltd. is not without risks. The PEG Forward ratio of 1.62 suggests that growth may not be as cheap as it appears. Additionally, the Price/Sales ratio of 2.36 and Price/Book of 1.34 could indicate that the stock is not as undervalued as some might hope. With the stock trading close to its 52-week high, there is a risk of technical overextension, which could deter cautious investors.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Hold

Average Analyst Price Target

$17.00

Institutional Ownership %

1-Year Beta

1.98

Insider Buying % (6 Mo)

Distance to 52-Week High

19.15%

Distance to 52-Week Low

9.47%

EARNINGS SURPRISE %

-16.05%

50-DAY SMA

$13.96

200-DAY SMA

$14.45

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.